tbuckley/cabot-search huggingface dataset:
Infiltrative Lymphoma-Associated Bradycardia and Cardiac Conduction Abnormalities
Authors: Pritha Subramanyam, Syed S. Mahmood, William Dinsfriend, Raymond D. Pastore, Peter Martin, Angel T. Chan, Jonathan W. Weinsaft, Jim W. Cheung
Journal: JACC CardioOncology (2020)

In 2015, a 31-year-old woman presented with cough and lymphadenopathy. On positron emission tomography-computed tomography (PET-CT), she was found to have cervical and mediastinal lymph node involvement and superior vena cava encasement. Open left neck lymph node biopsy confirmed the diagnosis of
HSR20-105: The Impact of Gastric Cancer Clinical Pathways Based on National Comprehensive Cancer Network Guidelines on Treatment Heterogeneity and Clinical Outcomes in the US Oncology Network
Authors: Scott Paulson, Curtis Waycaster, Bismark Baidoo, Astra M. Liepa, Anindya Chatterjee, Lisa M. Hess
Journal: Journal of the National Comprehensive Cancer Network (2020)

"HSR20-105: The Impact of Gastric Cancer Clinical Pathways Based on National Comprehensive Cancer Network Guidelines on Treatment Heterogeneity and Clinical Outcomes in the US Oncology Network" published on 20 Mar 2020 by National Comprehensive Cancer Network.
A PILOT STUDY OF PATIENTS UNDERGOING TRANSCATHETER PARAVALVULAR LEAK CLOSURE WITH FLUOROSCOPY TRUEFUSION INTEGRATED TEE GUIDANCE
Authors: Danielle Sin, Homam Ibrahim, Illya Pushkar, Priya Gaiha, Alan Vainrib, Hasan Jilaihawi, Cezar Staniloae, Mathew Williams
Journal: Journal of the American College of Cardiology (2020)
MYOCARDIAL INTERSTITIAL FIBROSIS IS INCREASED IN LEFT VENTRICULAR NON-COMPACTION AND PREDICTS DROP IN SYSTOLIC FUNCTION
Authors: Nijas Nazar, Carlos Santos-Gallego, Shehanaz Shajahan, Rebecca Smoller, Valentin Fuster, Juan J. Badimon, Javier Sanz
Journal: Journal of the American College of Cardiology (2020)
THE ASSOCIATION BETWEEN POLYVASCULAR DISEASE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME
Authors: Subodh Verma, C. David Mazer, Silvio E. Inzucchi, Christoph Wanner, Anne Pernille Ofstad, Odd Erik Johansen, Isabella Zwiener, Jyothis T. George, Javed Butler, Bernard Zinman
Journal: Journal of the American College of Cardiology (2020)
Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
Authors: Michaël H. Meel, Mark C. de Gooijer, Dennis S. Metselaar, A. Charlotte P. Sewing, Kenn Zwaan, Piotr Waranecki, Marjolein Breur, Levi C.M. Buil, Tonny Lagerweij, Laurine E. Wedekind, Jos W.R. Twisk, Jan Koster, Rintaro Hashizume, Eric H. Raabe, Ángel Montero Carcaboso, Marianna Bugiani, Timothy N. Phoenix, Olaf van Tellingen, Dannis G. van Vuurden, Gertjan J.L. Kaspers, Esther Hulleman
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Diffuse intrinsic pontine glioma (DIPG) is an incurable type of pediatric brain cancer, which in the majority of cases is driven by mutations in genes encoding histone 3 (H3K27M). We here determined the preclinical therapeutic potential of combined AXL and HDAC inhibition in these tumors to reverse their mesenchymal, therapy-resistant, phenotype. Experimental Design: We used public databases and patient-derived DIPG cells to identify putative drivers of the mesenchymal transition in these tumors. Patient-derived neurospheres, xenografts, and allografts were used to determine the therapeutic potential of combined AXL/HDAC inhibition for the treatment of DIPG. Results: We identified AXL as a therapeutic target and regulator of the mesenchymal transition in DIPG. Combined AXL and HDAC inhibition had a synergistic and selective antitumor effect on H3K27M DIPG cells. Treatment of DIPG cells with the AXL inhibitor BGB324 and the HDAC inhibitor panobinostat resulted in a decreased expression of mesenchymal and stem cell genes. Moreover, this combination treatment decreased expression of DNA damage repair genes in DIPG cells, strongly sensitizing them to radiation. Pharmacokinetic studies showed that BGB324, like panobinostat, crosses the blood–brain barrier. Consequently, treatment of patient-derived DIPG xenograft and murine DIPG allograft-bearing mice with BGB324 and panobinostat resulted in a synergistic antitumor effect and prolonged survival. Conclusions: Combined inhibition of AXL and HDACs in DIPG cells results in a synergistic antitumor effect by reversing their mesenchymal, stem cell-like, therapy-resistant phenotype. As such, this treatment combination may serve as part of a future multimodal therapeutic strategy for DIPG.
Long-term survival following robot-assisted surgical treatment of early cervical cancer.
Authors: Amanda Lynn Jackson, Joshua Kilgore, Emily Meichun Ko, Renatta Craven, Paola A. Gehrig, John T. Soper, John Boggess
Journal: Journal of Clinical Oncology (2013)

5607 Background: To determine progression-free survival (PFS) and overall survival (OS) for patients with early stage cervical cancer surgically treated using robotic-assisted laparoscopy compared to open radical hysterectomy. Methods: A retrospective analysis of women that underwent a robotic-assisted surgery (RAS) for early stage cervical cancer was performed. Surgical procedures included radical hysterectomy, parametrectomy, and trachelectomy from 2005 to May 2012. Patient demographics, clinicopathologic data, and disease status were analyzed. Comparison was made to open radical hysterectomies (ORH) from 2000 to May 2012. Survival statistics were analyzed using the Kaplan-Meier method. Results: 147 patients underwent RAS; 97 patients underwent ORH in our comparison group. Surgery was aborted in 8 RAS and 5 ORH due to extent of disease. The robotic surgical treatments included 121 (82.3%) radical hysterectomies, 14 (9.5%) trachelectomies, and 12 (8.2%) parametrectomies. In the RAS, the mean age was 44.3 (range 17-75); the mean body mass index (BMI) was 27.7 (range 16-50). Most patients presented with clinical stage IBI disease (79.9%). Squamous cell histology was most common (55.4%) followed by adenosquamous (36.7%). No significant differences were found between the RAS and ORH with regards age, BMI, surgical stage, grade, short and long-term complications, and comorbidities. The mean follow up time was 24.7 (range 0-82.1) months. Recurrence was documented in 3 patients after RAS and 11 patients after ORH; 3 deaths were recorded in the RAS group and 10 in the ORH. One patient had persistent adenocarcinoma in situ after robotic trachelectomy. Compared to ORH, there was a significantly better PFS in RAS (HR .312, CI 0 .099-0.98, p = 0.046) while no difference was seen in OS (p = 0.172). Conclusions: The results demonstrate that RAS is associated with lower rates of recurrence and no difference in overall survival. These findings provide further evidence that robotic-assisted surgical treatment is not associated with inferior results when compared to laparotomy or traditional laparoscopy. As robotic-assisted surgery is associated with a less steep learning curve, it may become the surgical approach of choice.
The role of GATA4 and GATA6 as putative tumor suppressors and co-modulators in astrocytes
Authors: Deepak Kamnasaran, Sameer Agnihotri, Cynthia Hawkins, Abhijit Guha
Journal: Cancer Research (2007)

372  Introduction: Astrocytomas compromise over 60% of all primary human adult central nervous system neoplasms, with Glioblastoma Multiforme (GBM) being the most common and malignant. Our group has previously used an oncogenic V12Ha-Ras mouse model (GEM) for astrocytomas as a “gene-discovery” reagent to screen for genetic modifiers, and identified GATA6 as a late progression tumor suppressor gene (TSG) in both murine and human astrocytomas. Furthermore, using a candidate gene approach, we identified GATA4, a member of the same GATA family of transcription factors, as a possible TSG in gliomas. Our overall objective was to examine the function and expression of both GATA4 and GATA6 in normal and transformed human and murine astrocytes.  Methods-Results:  Using Real time RT-PCR and western blot analysis, we identified GATA4 as a positive regulator of GATA6 expression, and vice versa in newborn (P0) murine astrocytes but not in adult normal human astrocytes (immortalized with TERT) and in transformed astrocytes (glioma cell lines). The expression of effector genes such as DAB2, WNT7a and BMP2 were regulated positively by both GATA4 and GATA6, unlike some genes such as HNF4a that is regulated only by GATA6. We studied our oncogenic V12Ha-Ras GEM for gliomas and identified both GATA4 and GATA6 as expressed in the low grade astrocytomas (LGA) but with absent expression in high grade astrocytomas (HGA). We next examined panels of human glioma specimens (glioma cell lines, GBM xenografts explants, surgical specimens) using western blot analysis, RT-PCR and immunohistochemistry. We noted the majority of HGAs (60-85%) but only 10-33% of LGAs, with loss of GATA4 and GATA6 expression. We did not find any statistically significant correlation between concurrent altered expression of GATA4 and GATA6, however while more LGAs had loss of GATA4 expression, more HGAs had loss of GATA6 expression.  Discussion:  Both GATA4 and GATA6 have been implicated as TSGs in cancers such as adrenocortical, gastric and ovarian. We are the first to demonstrate transcriptional regulatory cross talks between GATA4 and GATA6 in astrocytes, with roles as late progression factors in gliomas. Both GATA4 and GATA6 plus their effectors can therefore serve as excellent therapeutic targets in the treatment of gliomas.
HEART FAILURE EVENTS AFTER TYPE 2 MYOCARDIAL INFARCTION
Authors: Cian P. McCarthy, Sean Murphy, Saad Rehman, Maeve Jones-O'Connor, David Olshan, Joshua Cohen, Jinghan Cui, Avinainder Singh, Muthiah Vaduganathan, James Januzzi, Jason H. Wasfy
Journal: Journal of the American College of Cardiology (2020)
TEMPORAL TRENDS IN MECHANICAL CIRCULATORY SUPPORT USE AND DOOR-TO-UNLOADING TIME IN A STEMI POPULATION OVER NEARLY A DECADE
Authors: Michael Brener, Hannah Rosenblum, Lauren Sharan Ranard, Amirali Masoumi, Justin Fried, Sorin J. Brener, Megha Prasad, Yousif Ahmad, Dimitrios Karmpaliotis, Ajay Kirtane, Leroy Rabbani, Arthur R. Garan
Journal: Journal of the American College of Cardiology (2020)
CAR T Cell Therapy–Related Cardiovascular Outcomes and Management
Authors: Arjun K. Ghosh, Daniel H. Chen, Avirup Guha, Strachan Mackenzie, J. Malcolm Walker, Claire Roddie
Journal: JACC CardioOncology (2020)

CD19-specific chimeric antigen receptor (CAR) T cell therapies have shown remarkable early success in highly refractory and relapsing hematological malignancies. However, this potent therapy is accompanied by significant toxicity. Cytokine release syndrome and neurotoxicity are the most widely reported, but the true extent and characteristics of cardiovascular toxicity remain poorly understood. Thus far, adverse cardiovascular effects observed include sinus tachycardia and other arrhythmias, left ventricular systolic dysfunction, profound hypotension, and shock requiring inotropic support. The literature regarding cardiovascular toxicities remains sparse; prospective studies are needed to define the cardiac safety of CAR T cell therapies to optimally harness their potential. This review summarizes the current understanding of the potential cardiovascular toxicities of CD19-specific CAR T cell therapies, outlines a proposed cardiac surveillance protocol for patients receiving this new treatment, and provides a roadmap of the future direction of cardio-oncology research in this area.
Barriers to patient adherence with adjuvant endocrine therapy.
Authors: Jennifer Michelle Duff, Hui Yan, Myron Chang, Eric Rosenberg, Karen Colleen Daily
Journal: Journal of Clinical Oncology (2013)

6605 Background: Adjuvant endocrine therapy for hormone receptor positive breast cancer is essential to decreasing recurrence and improving survival. However, adherence to these drugs has been reported to be suboptimal, the impact of which on breast cancer outcomes is unknown. Multiple non-modifiable risk factors have been associated with nonadherence. Identifying patients’ self-reported reasons for not taking these drugs as prescribed may be crucial to improving adherence. Methods: We obtained data from 49 women prescribed tamoxifen, letrozole, anastrozole, or exemestane for stage I-III invasive breast cancer. Written surveys were provided during the patients’ medical oncology visits. Our study collected demographic data on patient characteristics associated with nonadherence. Patients were asked to report reasons for missing doses including forgetting to take the drug, side effects, cost, and barriers to refill. Patients described their degree of adherence by identifying how often they miss a dose as never, once per month, once per week, or more than once per week. We compared their self-reported adherence to pharmacy refill records. Results: More than half the women (26 of 49) report regularly missing doses of their drug over the last year. Of these, 22 miss once per month, 3 miss once per week, and 1 misses more than once per week. Despite this, pharmacy records verified consistent refills in all 26 less adherent patients over the past year. The most common reason identified for missed doses (21 of 26) was forgetting to take the drug, followed by barriers to refill and side effects. 57% of all patients favored receiving an electronic reminder via text messaging or email. Nonadherence was associated with polypharmacy and lower levels of education, income, and activity. Conclusions: Our study provides insight into patient reported reasons for nonadherence to adjuvant endocrine therapy. Our patients reported forgetting to take their drug as most problematic. Patients’ self-reported adherence was confirmed (96%) by pharmacy records. Most patients are interested in an electronic reminder system via e-mail or text messaging, even if they report complete adherence. This has potential to be a cost effective intervention.
INCIDENCE AND PROGNOSIS OF CARDIAC ALLOGRAFT VASCULOPATHY IN HEART TRANSPLANT PATIENTS
Authors: Michel Zeitouni, Johanne Silvain, Matthieu Steinecker, Guillaume Godeau, Niki Procopi, Benoit Lattuca, Stéphanie Rouanet, Lee S. Nguyen, Guillaume Coutance, Guillaume Lebreton, Mathieu Kerneis, Olivier Barthelemy, Jean-Philippe Collet, Shaida Varnous, Pascal Leprince, Gilles Montalescot
Journal: Journal of the American College of Cardiology (2020)
STROKE RISK IN PATIENTS WITH PAROXYSMAL AND PERSISTENT ATRIAL FIBRILLATION TREATED WITH ANTI-ARRHYTHMIC DRUGS VS. CATHETER ABLATION
Authors: Sanghamitra Mohanty, Chintan Trivedi, Domenico Della Rocca, Carola Gianni, Mohamed Bassiouny, Anu Salwan, Alisara Anannab, Bryan Macdonald, Angel Mayedo, John Burkhardt, Gerald Gallinghouse, Amin Al-Ahmad, Rodney Horton, Luigi Di Biase, Andrea Natale
Journal: Journal of the American College of Cardiology (2020)
Effect of enobosarm on physical function in cancer patients with &lt; or ≥ 5% weight loss in a phase IIb trial.
Authors: Shontelle Dodson, Mary Ann Johnston, Michael L. Hancock, Mitchell S. Steiner
Journal: Journal of Clinical Oncology (2012)

e19585 Background: Although cachexia has been defined as &gt;5% weight loss, limited data exists on the prevention and treatment of muscle wasting prior to a patient becoming cachectic. Cancer induced muscle wasting can begin early in the course of a patient’s malignancy resulting in decline in physical function and other detrimental clinical consequences including less tolerability to chemotherapy, worse outcomes, and shorter survival - underscoring the importance of diagnosing and treating this condition at an early stage. Methods: We conducted a randomized, double blind, placebo controlled, multi-center study to evaluate the effect of enobosarm on physical function and muscle wasting in cancer patients. Subjects (n=159) were randomized to oral enobosarm or placebo for 16 weeks. Subjects were males &gt;45y and postmenopausal females, with ≥2% weight loss in the 6 months prior to randomization and diagnosed with NSCLC, colorectal cancer, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia or breast cancer. We report on changes in physical function based on weight loss of &lt; or ≥5%in the 6 months prior to randomization. Results: 103 subjects (MITT) had physical function assessed by stair climb at baseline and week 16 with 24% losing &lt;5% weight in the previous 6 months. Distribution of weight loss was similar across genders, however subjects with &lt;5% weight loss were more likely to be ECOG=0 (&lt;5% loss: 46.2%; ≥5% loss: 35.8%). Subjects with ≥5% weight loss had worse physical function at baseline compared to those with &lt;5% loss (p=0.048). A significant improvement in physical function was observed in subjects that received enobosarm regardless of baseline weight loss (&lt;5% loss, p=0.041, ≥5% loss, p&lt;0.001) while subjects that received placebo failed to improve. Conclusions: Enobosarm was generally well tolerated and showed a statistically significant improvement in physical function in cancer subjects regardless of baseline weight loss. These data provide evidence that enobosarm may play an important role in the management of cancer patients by not only treating, but also preventing further decline in physical function and muscle wasting before a patient becomes cachectic.
PREVALENCE OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A POPULATION BASED STUDY
Authors: Omar Farid Abou-Ezzeddine, Daniel Davies, Jasmine A. Sexton, Christopher G. Scott, Ahmed Fayyaz, Nadia Akhiyat, Trevor A. Stromme, John W. Askew, Paul McKie, Peter Noseworthy, Shannon Dunlay, Barry Borlaug, Panithaya Chareonthaitawee, Geoffrey Johnson, Angela Dispenzieri, Martha Grogan, Margaret M. Redfield
Journal: Journal of the American College of Cardiology (2020)
FASTER PROGRESSION OF LEFT VENTRICULAR THICKNESS IN MEN COMPARED TO WOMEN IN WILD-TYPE TRANSTHYRETIN CARDIAC AMYLOIDOSIS
Authors: Syed Bukhari, Amr Barakat, Suresh Mulukutla, Floyd Thoma, Yvonne S. Eisele, Ricardo Nieves, Daniel Shpilsky, Prem Soman
Journal: Journal of the American College of Cardiology (2020)
CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT WITH AND WITHOUT UNDERLYING MALIGNANCY
Authors: Kamalpreet Dhaliwal, Beni Rai Verma, Manpreet Kaur, Shameer Khubber, Sonia Randhawa, Hafiz Umair Siddiqui, Najdat Bazarbashi, Mohamed M. Gad, Keerat Rai Ahuja, Zoran Popovic, Grant W. Reed, Rishi Puri, Amar Krishnaswamy, Lars G. Svensson, E. Murat Tuzcu, Rhonda Lahiri Miyasaka, Shinya Unai, James Yun, Usman Ahmad, Samir R. Kapadia
Journal: Journal of the American College of Cardiology (2020)
NOT A TYPICAL SYNCOPE: AN UNUSUAL PRESENTATION OF YAMAGUCHI CARDIOMYOPATHY
Authors: Migdoel Cruz, Dagmar Hernandez-Suarez, Fiorella Rodriguez-Rivera, Sharlene Medina Aviles, Jorge Juan Ballester Maldonado, Isamuel Santos, Pedro Enrique Vargas Otero
Journal: Journal of the American College of Cardiology (2020)
Scoring system predicting overall survival (OS) in patients (Pts) with non-small cell lung cancer (NSCLC).
Authors: Steven E. Schild, Angelina D. Tan, Jason A. Wampfler, Julian R. Molina, Helen J. Ross, Ping Yang, Jeff A. Sloan
Journal: Journal of Clinical Oncology (2013)

7545 Background: Interpretation of lung cancer clinical trials is complicated by the heterogeneity of the patient population due to disease burden and comorbidities making pre-trial assessment of OS probability challenging. Methods: To create and validate a scoring system to estimate OS and improve the quality of future trials, this study evaluated the pretreatment prognostic factors of 2,442 pts with NSCLC. Univariate (UV) and multivariate (MV) Cox models were used to evaluate the prognostic importance of each baseline factor on OS. Those prognostic factors significant on both UV and MV analyses that were used to develop the scoring system included overall quality of life, age, sex, stage, ECOG performance status, the presence of other cancers, and smoking cessation. The score for each factor was determined by dividing the 5-year OS rate (in %) by 10 and summing these scores to form a total score. Multivariate models and the score for each factor were validated using bootstrapping with 1000 iterations from the original samples. Results: The score for each factor ranged from 1 to 7 points and the total scores ranged between 23 and 39 points. Higher scores reflected better OS. Categorization of the score was delineated first by clinician expert opinion (see Table) and then by multiple statistically defined empirical cut points. All categorization schemes demonstrated successful prognostic power. The bootstrap method confirmed the reliability of multivariate Cox model and score (Spearman correlation coefficient= 0.45). Conclusions: Prognostic factors significantly associated with OS on both UV and MV analysis were used to construct a valid scoring system which can be used to predict survival of NSCLC pts. This scoring system can be used by clinicians in counseling pts and for stratification in future trial design. [Table: see text]
OUTCOMES OF TRANSCATHETER MITRAL VALVE REPAIR IN ISCHEMIC VERSUS NON-ISCHEMIC CARDIOMYOPATHY: THE COAPT TRIAL
Authors: Karim Al-Azizi, Paul A. Grayburn, Molly Szerlip, Robert Smith, Mohanad Hamandi, Anna Sannino, Neil J. Weissman, Samir R. Kapadia, Rishi Puri, Grant W. Reed, Amar Krishnaswamy, Yiran Zhang, JoAnn Lindenfeld, William Abraham, Gregg W. Stone, Michael Mack
Journal: Journal of the American College of Cardiology (2020)
POLYVASCULAR DISEASE WITH AND WITHOUT DIABETES AND THE RISK OF ADVERSE CARDIOVASCULAR AND LIMB EVENTS IN THE EUCLID TRIAL
Authors: Sean Behan, Cecilia C. Low Wang, Connie Hess, Hillary Mulder, Antonio Gutierrez, Francis Fowkes, Iris Baumgartner, Jeffrey Berger, Brian Katona, Kenneth Mahaffey, Lars Norgren, Juuso Blomster, Schuyler Jones, Manesh R. Patel, William R. Hiatt, Marc P. Bonaca
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS ON CARDIAC REMODELING AND EXERCISE CAPACITY AFTER ACUTE MYOCARDIAL INFARCTION
Authors: Daisuke Kitano, Kazuto Toyama, Daisuke Fukamachi, Nobuhiro Murata, Yuki Saito, Mitsumasa Sudo, Sayaka Kurokawa, Yoshihiro Aizawa, Yasuo Okumura
Journal: Journal of the American College of Cardiology (2020)
Skn-1a(Pou2f3)は味覚受容器細胞系譜を規定する | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Matsumoto Ichiro, Ohmoto Makoto, Narukawa Masataka, Yoshihara Yoshihiro, Abe Keiko
Journal: Nature Neuroscience (2011)
EFFECT OF ELECTIVE PERCUTANEOUS CORONARY INTERVENTION ON HYPEREMIC ABSOLUTE CORONARY BLOOD FLOW VOLUME AND MICROVASCULAR RESISTANCE EVALUATED BY TRANSTHORACIC DOPPLER ECHOCARDIOGRAPHY
Authors: Masao Yamaguchi, Masahiro Hoshino, Kai Nogami, Hiroki Ueno, Hidenori Hirano, Toru Misawa, Masahiro Hada, Yohei Sumino, Yoshihisa Kanaji, Tomoyo Sugiyama, Taishi Yonetsu, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2020)
RATE, CAUSES AND PREDICTORS OF 30-DAY READMISSIONS FOLLOWING CORONARY ARTERY BYPASS GRAFTING IN THE UNITED STATES
Authors: Jayakumar Sreenivasan, Urvashi Hooda, Wilbert S. Aronow, David Spielvogel, Howard A. Cooper, Steven Lansman, Julio Panza
Journal: Journal of the American College of Cardiology (2020)
Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts
Authors: Andrew J. Robles, Raushan T. Kurmasheva, Abhik Bandyopadhyay, Doris A. Phelps, Stephen W. Erickson, Zhao Lai, Dias Kurmashev, Yidong Chen, Malcom A. Smith, Peter J. Houghton
Journal: Clinical Cancer Research (2020)

Vincristine combined with camptothecin derivatives showed synergy in preclinical pediatric cancer models, and the combinations are effective in treatment of childhood solid tumors. We determined whether the synergy between vincristine and irinotecan extends to eribulin, another microtubule inhibitor.